BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 12386924)

  • 1. Cyclooxygenase-2 promotes prostate cancer progression.
    Fujita H; Koshida K; Keller ET; Takahashi Y; Yoshimito T; Namiki M; Mizokami A
    Prostate; 2002 Nov; 53(3):232-40. PubMed ID: 12386924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F; RosanĂ² L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
    Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer.
    Gupta RA; Tejada LV; Tong BJ; Das SK; Morrow JD; Dey SK; DuBois RN
    Cancer Res; 2003 Mar; 63(5):906-11. PubMed ID: 12615701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells.
    Han S; Inoue H; Flowers LC; Sidell N
    Clin Cancer Res; 2003 Oct; 9(12):4627-35. PubMed ID: 14555539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
    Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
    Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells.
    Subbarayan V; Sabichi AL; Llansa N; Lippman SM; Menter DG
    Cancer Res; 2001 Mar; 61(6):2720-6. PubMed ID: 11289153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
    Zha S; Gage WR; Sauvageot J; Saria EA; Putzi MJ; Ewing CM; Faith DA; Nelson WG; De Marzo AM; Isaacs WB
    Cancer Res; 2001 Dec; 61(24):8617-23. PubMed ID: 11751373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.
    Inoue K; Slaton JW; Eve BY; Kim SJ; Perrotte P; Balbay MD; Yano S; Bar-Eli M; Radinsky R; Pettaway CA; Dinney CP
    Clin Cancer Res; 2000 May; 6(5):2104-19. PubMed ID: 10815938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
    Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
    Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
    Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
    Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
    Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
    Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
    Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
    Wen B; Deutsch E; Eschwege P; De Crevoisier R; Nasr E; Eschwege F; Bourhis J
    J Urol; 2003 Nov; 170(5):2036-9. PubMed ID: 14532848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line.
    Liu XH; Kirschenbaum A; Yao S; Stearns ME; Holland JF; Claffey K; Levine AC
    Clin Exp Metastasis; 1999; 17(8):687-94. PubMed ID: 10919714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells.
    Levine L; Lucci JA; Pazdrak B; Cheng JZ; Guo YS; Townsend CM; Hellmich MR
    Cancer Res; 2003 Jul; 63(13):3495-502. PubMed ID: 12839933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.
    Liu XH; Yao S; Kirschenbaum A; Levine AC
    Cancer Res; 1998 Oct; 58(19):4245-9. PubMed ID: 9766645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma.
    Cheng AS; Chan HL; To KF; Leung WK; Chan KK; Liew CT; Sung JJ
    Int J Oncol; 2004 Apr; 24(4):853-60. PubMed ID: 15010822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.